½ÃÀ庸°í¼­
»óǰÄÚµå
1568901

¼¼°èÀÇ ÀǾàǰ »ó¾÷È­ ¼Ö·ç¼Ç ¹× ¼­ºñ½º »ê¾÷(2024-2029³â)

Pharmaceutical Commercialization Solutions and Services Industry, Global, 2024-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Frost & Sullivan | ÆäÀÌÁö Á¤º¸: ¿µ¹® 89 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

SaaS ±â¹Ý ¼­ºñ½º Ç÷§Æû¿¡ ±â¹ÝÇÑ Çõ½ÅÀûÀÎ Á¤¹Ð ¸¶ÄÉÆÃ°ú ÇÁ·Î±×·¡¸Åƽ ¸¶ÄÉÆÃ Á¢±Ù ¹æ½ÄÀ¸·Î ÀǾàǰÀÇ »ó¾÷È­¸¦ ÃËÁøÇÕ´Ï´Ù.

ȯÀÚ Áß½ÉÀÇ ÀÇ·á Á¦°ø ¹æ½Ä¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó Á¦¾à¾÷°è´Â ½ÃÀå ÀÌÇØ°ü°èÀÚ, ºÎ¹®, ½ÃÀå Ãâ½Ã ÈÄ ¿¹ÃøÀ» ¸íÈ®È÷ ÀÌÇØÇÏ°í ¿øÈ°ÇÑ ½ÃÀå ÁøÃâ Àü·«À» ¼ö¸³ÇÏ¿© ½ÃÀå »ó¿ëÈ­¸¦ À§ÇÑ ´Ü°èº° Á¢±Ù ¹æ½ÄÀ» µû¸£°í ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº Áö¿ªº°·Î ½Ã½Ã°¢°¢ º¯È­ÇÏ´Â ½ÃÀå »óȲ¿¡ ´ëÀÀÇϱâ À§ÇØ Á¦3ÀÚ ¹°·ù¾÷ü¿Í Çù·ÂÇÏ¿© ÀÌÁß Á¶´Þ, ºñÃà, °íµµÀÇ ½Ã³ª¸®¿À °èȹ°ú °°Àº ÀûÀÀÇü °ø±Þ¸Á Àü·«À» äÅÃÇÏ´Â ÇÑÆí, ±âÁ¸ À¯Åë ÆÄÆ®³ÊÀÇ ¿ª·®À» Ȱ¿ëÇÏ¿© À¯Åë À§Çè°ú È¥¶õÀ» ÇÇÇϰí ÀÖ½À´Ï´Ù. Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ¸¶ÄÉÆÃ ¹× ÆÇ¸Å Àü·«Àº Á¦¾à»ç°¡ ÀÌÇØ°ü°èÀÚ, ±ÔÁ¦ ±â°ü, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±âŸ ±â¼ú °ø±Þ¾÷ü¶ó´Â Å« ¹Ù´Ù¸¦ Ç×ÇØÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾î ÀÖ½À´Ï´Ù. Á¦¾à»çÀÇ ¸¶ÄÉÆÃÀº °úÇÐÀû µ¥ÀÌÅÍ, Áõ¾ð ¹× ±âŸ ´Ù¾çÇÑ Á¤º¸¸¦ »ç¿ëÇÏ¿© HCP(ÀÇ·áÁø)µé »çÀÌ¿¡¼­ ±àÁ¤ÀûÀÎ À̹ÌÁö¿Í ½Å·Ú¸¦ Çü¼ºÇÏ¿© Á¦Ç° ÀÎÁöµµ¸¦ ³ôÀ̰í, ÀÌÈÄ ¾à¹° º¹¿ëÀ» ÃËÁøÇϱâ À§ÇØ ³ë·ÂÇÕ´Ï´Ù. Á¦¾à»ç´Â Á¦Ç°ÀÇ °¡Ä¡ Á¦¾È¿¡ ±â¹ÝÇÑ ¸ñÇ¥ ½ÃÀå ÆÄ¾ÇºÎÅÍ ÃÖÁ¾ »ç¿ëÀÚÀÇ °üÁ¡ º¯È­ ÀÌÇØ, °æÀï ¿ìÀ§¸¦ À¯ÁöÇϱâ À§ÇØ ÇÊ¿äÇÑ º¯È­±îÁö ¸ðµÎ Æ÷ÇÔÇÏ´Â ´Ü°èÀû Á¢±Ù ¹æ½ÄÀ» äÅÃÇÏ¿© »ó¾÷Àû ½ÃÀå ÁøÀÔÀ» À§ÇÑ ´Ü°èº° Á¢±Ù ¹æ½ÄÀ» äÅÃÇØ¾ß ÇÕ´Ï´Ù. ÀÚµ¿È­¿Í AI, ML, Ŭ¶ó¿ìµå ¼Ö·ç¼ÇÀÇ È°¿ëÀº Á¦¾à»çÀÇ »ó¾÷Àû ¾÷¹« È®Àå¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ½ÃÀå ¼¼ºÐÈ­, ÄÁÅÙÃ÷ °³ÀÎÈ­, ¸®µå ½Äº° ¹× Á¡¼öÈ­, ÈÄ¼Ó ½ÃÀå Á¢±ÙÀ» À§ÇØ ¿¹Ãø ºÐ¼®À» »ç¿ëÇÏ¿© ´õ ³ªÀº Á¦Ç° ÀΰÔÀÌÁö¸ÕÆ®¿Í ¼öÀÍÀ» º¸ÀåÇÕ´Ï´Ù. Á¦¾àȸ»ç¿Í º¥´õ´Â »ó¾÷È­ ¼º°øÀ» Çâ»ó½Ã۱â À§ÇØ ¾÷°è Àü¹ÝÀÇ Çù¾÷¿¡ ÁÖ¸ñÇØ¾ß ÇÕ´Ï´Ù. ÀÌ ºÐ¼®Àº HEOR ¼Ö·ç¼Ç, ¸ÂÃãÇü/Á¤È®ÇÑ ¿È´Ïä³Î ¸¶ÄÉÆÃ Àü·«, ÁöºÒÀÚ¿Í PBMÀ» À§ÇÑ ÅëÇÕ ¾à°¡ ½ÃÀå ±âȸ¸¦ ½ÉÃþÀûÀ¸·Î »ìÆìº¸°í, ¼­ºñ½º ¸ðµ¨/°è¾à À¯Çüº°·Î ¿¹ÃøÀ» ºÐ·ùÇÕ´Ï´Ù.

¸ñÂ÷

¼ºÀå ȯ°æ : ÀǾàǰ »ó¾÷È­ ¼Ö·ç¼Ç°ú ¼­ºñ½º ºÐ¾ßÀÇ º¯Çõ

  • ¿Ö ¼ºÀåÀÌ ¾î·Á¿öÁö°í Àִ°¡?
  • The Strategic Imperative 8(TM)
  • ÀǾàǰ »ó¾÷È­ ¼Ö·ç¼Ç°ú ¼­ºñ½º ¾÷°è¿¡ ´ëÇÑ TOP 3 Àü·«ÀÇ ¿µÇâ

¼ºÀå ȯ°æ : ÀǾàǰ »ó¾÷È­ ¼Ö·ç¼Ç°ú ¼­ºñ½º ºÐ¾ß ¿¡ÄڽýºÅÛ

  • ºÐ¼® ¹üÀ§
  • ½ÃÀåÀÇ Á¤ÀÇ, ¹üÀ§, ¼¼ºÐÈ­
  • »ó¾÷ ¼­ºñ½º ¸ðµ¨/ÆÄÆ®³Ê½Ê À¯Çü¿¡ ÀÇÇÑ ¼¼ºÐÈ­
  • ÀǾàǰ »ó¾÷ ¹ë·ùüÀÎ - »ó¾÷ ¾Ö³Î¸®Æ½½º °³¿ä
  • ½ÃÀå µ¿Ç⠺м®
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ

¼ºÀå ȯ°æ : ÀǾàǰ »ó¾÷ ¼­ºñ½º

  • ÀǾàǰ Ãâ½Ã - ÁÖ¿ä ¾÷¹«¿Í ÀÌÇØ°ü°èÀÚ
  • ÀǾàǰ ¸¶ÄÉÆÃ°ú ÆÇ¸ÅÀÇ ÁÖ¿ä Ãø¸é
  • ÀǾàǰ ½ÃÀå Âü¿© ÇÁ·Î¼¼½ºÀÇ ÁÖ¿ä Ãø¸é
  • º¥´õ ¿¡ÄڽýºÅÛ

¼ºÀå ȯ°æ : ÀǾàǰ »ó¾÷ ¼­ºñ½º

  • ÀÌÇØ°ü°èÀÚ¿¡ ÀÇÇÑ »ó¾÷È­¸¦ À§ÇÑ µðÁöÅÐ ¼Ö·ç¼Ç
  • Á¦¾à ±â¾÷ »ó¾÷ Ȱµ¿ Å×Å©³î·¯Áö Ȱ¿ë
  • ¹ë·ùüÀο¡¼­ÀÇ AI Ȱ¿ë
  • È¿°úÀûÀÎ Ä¿¹Â´ÏÄÉÀ̼ÇÀ» À§ÇÑ µðÁöÅÐ ¸¶ÄÉÆÃ Àü·«
  • µðÁöÅÐ ¸¶ÄÏ ¾×¼¼½º Àü·«
  • ȯÀÚ Á᫐ ÀǾàǰ »ó¾÷È­¸¦ À§ÇÑ µðÁöÅÐ Àüȯ µµÀÔ

¼ºÀå ȯ°æ : ÀǾàǰ »ó¾÷ ¼­ºñ½º

  • ÅõÀÚ µ¿Çâ
  • ÅõÀÚ µ¿Çâ - ±â¼ú Àμö/ÆÄÆ®³Ê½Ê
  • ÅõÀÚ µ¿Çâ - Àü·«Àû ÆÄÆ®³Ê½Ê
  • ÅõÀÚ µ¿Çâ - ÇÕº´/Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã - »ç¾÷ È®´ë

¼ºÀå ȯ°æ : ÇൿÇÏ´Â ±â¾÷(C2A), ÀǾàǰ »ó¾÷È­ ¼Ö·ç¼Ç°ú ¼­ºñ½º »ê¾÷ ºÎ¹®

  • °æÀï ȯ°æ
  • °æÀï Æò°¡ Ç»¾î Ç÷¹ÀÌ
  • °æÀï Æò°¡ CRO/CSO
  • °æÀï Æò°¡ ±â¼ú À̳×ÀÌºí·¯
  • °æÀï Æò°¡

¼ºÀå ±âȸ ºÐ¼® : ÀǾàǰ »ó¾÷È­ ¼Ö·ç¼Ç°ú ¼­ºñ½º »ê¾÷ ¼ºÀå¿äÀÎ

  • ¼ºÀå ÁöÇ¥
  • ¿¹Ãø ÀλçÀÌÆ® : Á¢±Ù°ú Á¶»ç ¹æ¹ý
  • ¿¹Ãø ÀλçÀÌÆ® : ÇѰè¿Í ÁÖÀÇÁ¡
  • ¸ÅÃâ°ú ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø : ¼Ö·ç¼Ç/¼­ºñ½º À¯Çüº°
  • ¸ÅÃâ ¿¹Ãø ºÐ¼®
  • ¸ÅÃâ ¿¹Ãø : ¼­ºñ½º ¸ðµ¨/°è¾à À¯Çüº°
  • ¸ÅÃâ ¿¹Ãø ºÐ¼® : ¼­ºñ½º ¸ðµ¨/°è¾à À¯Çüº°

¼ºÀå ±âȸ ºÐ¼® : ÀǾàǰ »ó¾÷È­ ¼Ö·ç¼Ç°ú ¼­ºñ½º »ê¾÷ ¼ºÀå¿äÀÎ

  • Áö¿ª µ¿Ç⠺м® - ºÏ¹Ì
  • Áö¿ª µ¿Ç⠺м® - À¯·´
  • Áö¿ª µ¿Ç⠺м® - ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áö¿ª µ¿Ç⠺м® - ±âŸ ½ÅÈï ½ÃÀå

¼ºÀå ±âȸ

  • ¼ºÀå ±âȸ 1 : HEOR ¼­ºñ½º¸¦ À§ÇÑ ¸ÖƼ AI ¹× LLM ¿¡ÀÌÀüÆ®
  • ¼ºÀå ±âȸ 2 : PBM¿Í ÁöºÒÀÚ¸¦ À§ÇÑ ÅëÇÕ ¾à°¡ Àü·«
  • ¼ºÀå ±âȸ 3 : Á¤¹Ð ¸¶ÄÉÆÃ°ú ÆÇ¸Å Àü·«À» À§ÇÑ Çõ½ÅÀû Á¢±Ù

ÀǾàǰ »ó¾÷È­ ¼Ö·ç¼Ç°ú ¼­ºñ½º »ê¾÷ º£½ºÆ® ÇÁ·¢Æ¼½º Æò°¡

  • º£½ºÆ® ÇÁ·¢Æ¼½º Æò°¡

ÀǾàǰ »ó¾÷È­ ¼Ö·ç¼Ç°ú ¼­ºñ½º »ê¾÷¿¡¼­ÀÇ Frost Radar

  • Frost Radar

´ÙÀ½ ´Ü°è

  • ¼ºÀå ±âȸÀÇ ÀÌÁ¡°ú ¿µÇâ
  • ´ÙÀ½ ´Ü°è
  • µµÇ¥
  • ¸éÃ¥»çÇ×
LSH 24.10.31

Transformative Precision and Programmatic Marketing Approaches Backed by SaaS-based Service Platforms Drive Pharmaceutical Commercialization

With the growing preference for a patient-centric care delivery approach, the pharma industry follows a robust step-by-step approach towards market commercialization, with a clear understanding of the market stakeholders, segments, as well as post-launch forecasts to create seamless go-to-market strategies. To cater to the ever-evolving market landscapes across geographies, pharma companies are collaborating with third-party logistics and adopting adaptive supply chain strategies, such as dual sourcing, stockpiling, and advanced scenario planning, while tapping into established distribution partners' capabilities to avoid distribution risks and disruptions. As a result, marketing and sales strategies are designed to allow pharma companies to navigate the sea of stakeholders, regulatory bodies, end users, and other technology vendors. To increase product awareness and subsequent uptake, pharma marketing creates a positive image and confidence amongst HCPs for drug adoption using scientific data, testimonials, and many more. Pharma companies will have to adopt a step-by-step approach toward commercial market access, which involves everything from identifying the target market based on the product value proposition to understanding changes in end-user perspective and making the necessary alterations to maintain a competitive edge. Automation and the use of AI, ML, and cloud solutions will be instrumental in upscaling pharma commercial operations. These tools use predictive analytics for market segmentation, content personalization, lead identification and scoring, and subsequent market access, thereby ensuring better product uptake and revenue. Pharma companies and vendors must look at industry cross-collaborations that will improve commercialization success. This analysis dives deep into market opportunities available in HEOR solutions, tailormade/precision omnichannel marketing strategies, and integrated drug pricing for payers and PBMs and categorizes forecasts by service model/agreement type.

Table of Contents

Growth Environment: Transformation in Pharmaceutical Commercialization Solutions and Services Sector

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Pharmaceutical Commercial Solutions and Services Industry

Growth Environment: Ecosystem in Pharmaceutical Commercialization Solutions and Services Sector

  • Scope of Analysis
  • Market Definition, Scope and Segmentation
  • Segmentation by Commercial Services Model/Partnership Type
  • Pharmaceutical Commercial Value Chain-Commercial Analytics Overview
  • Market Trend Analysis
  • Growth Drivers
  • Growth Restraints

Growth Environment: Pharmaceutical Commercial Services

  • Pharmaceutical Commercial Launch-Primary Operations and Stakeholders involved
  • Key Aspects of Pharmaceutical Marketing and Sales
  • Key Aspects of Pharmaceutical Market Access Process
  • Vendor Ecosystem

Growth Environment: Pharmaceutical Commercial Services

  • Digital Solutions for Commercialization by Stakeholders
  • Technology Application across Pharma Commercial Activities
  • AI Application across the Commercialization Value Chain
  • Digital Marketing Strategies for Effective Communication
  • Digital Market Access Strategies
  • Embracing Digital Transformation for Patient-centric Pharma Commercialization

Growth Environment: Pharmaceutical Commercial Services

  • Investment Trends
  • Investment Trends-Technology Acquisition/Partnerships
  • Investment Trends-Strategic Partnerships
  • Investment Trends-Mergers & Acquisitions
  • New Product Launches-Expansions

Growth Environment: Companies to Action (C2A), Pharmaceutical Commercial Solutions and Services Sector

  • Competitive Environment
  • Competitor Assessment: Pure Play
  • Competitor Assessment: CROs/CSOs
  • Competitor Assessment: Tech Enablers
  • Competitor Assessment

Growth Opportunity Analysis: Growth Generator in Pharmaceutical Commercial Solutions and Services Sector

  • Growth Metrics
  • Forecast Considerations: Approach and Methodology
  • Forecast Considerations: Limitations and Caveats
  • Revenue Forecast
  • Revenue Forecast by Solution/Services Type
  • Revenue Forecast Analysis
  • Revenue Forecast By Service Model/Agreement Type
  • Revenue Forecast Analysis By Service Model/Agreement Type

Growth Opportunity Analysis: Growth Generator in Pharmaceutical Commercial Solutions and Services Industry

  • Regional Trend Analysis-North America
  • Regional Trend Analysis-Europe
  • Regional Trend Analysis-Asia Pacific
  • Regional Trend Analysis-Other Emerging Markets

Growth Opportunity Universe

  • Growth Opportunity 1: Multi AI and LLM agents for HEOR Services
  • Growth Opportunity 2: Integrated Drug Pricing Strategies for PBMs and Payors
  • Growth Opportunity 3: Innovative Approaches for Precision Marketing and Sales Strategies

Best Practices Recognition in Pharmaceutical Commercialization Solutions and Services Sector

  • Best Practices Recognition

Frost Radar in Pharmaceutical Commercialization Solutions and Services Sector

  • Frost Radar

Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • List of Exhibits
  • Legal Disclaimer
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦